All In MedTech

Device Trial Radar · NCT06931821

Functional ElectroAnatomiC Isochronal Late Activation Mapping for Empiric VT Ablation Trial

Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Apr 15, 2025

Primary completion

Apr 30, 2028

Study completion Apr 30, 2029

Sponsor

Lead sponsor
University of ArizonaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Abbott
First posted
Apr 17, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, prospective, parallel, randomized controlled trial to test for non-inferiority with an ILAM-guided VT ablation compared to conventional voltage- based ablation. The study has two treatment arms: conventional voltage mapping and ablation (control arm). In the investigational arm, the ablation strategy is guided by ILAM to target deceleration zones, blinded to voltage mapping. In the control arm, ablation will be performed to extensively ablate all low voltage regions (\<1.5mV) during sinus rhythm, right ventricular (RV) pacing, or left ventricular (LV) pacing, with discretionary use of pacemapping and activation mapping. In both arms, mapping with be performed with a multielectrode catheter (HD Grid) and ablation will be performed using an irrigated tip catheter (FlexAbility SE or Tactiflex catheters). In the control armonly voltage mapping displays will be utilized (blinded to functional ILAM and fractionation). High density mapping with automated last deflection annotation (Ensite X) will be performed in all patients randomized to ILAM approach during either sinus rhythm or RV pacing.

Conditions

  • Sustained Monomorphic VT (MMVT)
  • Recurrent Ventricular Tachycardia

Interventions

  • Isochronal Late Activation Mapping (ILAM)Device

    an isochronal late activation mapping (ILAM) display with automated last deflection annotation (EnSite X™) will be used to identify regions of isochronal crowding around a line of conduction block for targeted ablation therapy using a standard irrigated tip catheter (Flexability SE \& Tactiflex catheters)

  • High Density Voltage MappingDevice

    high-density voltage mapping will serve as the method to display the electroanatomic substrate for extensive and diffuse ablation within the low voltage area (\<1.5 mV).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Inducibility for VTTime frame: after initial 25 minutes of ablation (minutes of radiofrequency)
  2. Recurrent VTTime frame: 1 year post procedure
  3. CV HospitalizationTime frame: 1 year post procedure

2 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Banner University Medical Center Phoenix

    Phoenix, Arizona · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.